03:57 AM EDT, 10/01/2024 (MT Newswires) -- Kura Oncology ( KURA ) said late Monday a phase 1 study of its ziftomenib drug for the treatment of relapsed/refractory acute myeloid leukemia showed "encouraging" results.

Data from an 83-patient trial included in a paper published in The Lancet Oncology "expands the growing evidence supporting the efficacy and safety of ziftomenib in a disease indication of unmet need," said Ghayas C. Issa, a doctor who worked on the study.

The drug has received breakthrough therapy designation from the US Food and Drug Administration for the treatment of relapsed/refractory acute myeloid leukemia.